XBIO - Xenetic rises ~10% on upcoming Canadian patent for methods to improve cancer therapy

• Xenetic Biosciences ( NASDAQ: XBIO ) stock rose ~14% on Tuesday after the company said that the Canadian Intellectual Property Office (CIPO) issued a notice of allowance for a patent covering use of DNase enzyme for preventing or improving toxicity associated with chemotherapy.
• The patent for the application No. 3,001,543 titled, 'Method to Improve Safety and Efficacy of Anti-Cancer Therapy,' is expected to be issued in the coming months, according to the company.
• Xenetic noted that its interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies.
• The patent will covers claims including use of a therapeutically effective amount of a DNase enzyme for preventing or ameliorating a toxicity linked with a cytostatic and/or cytotoxic chemotherapy in patients with cancer.

For further details see: